Baird Downgrades Cellular Biomedicine Gr to Neutral, Lowers Price Target to $19

Baird downgrades Cellular Biomedicine Gr (NASDAQ:CBMG) from Outperform to Neutral and lowers the price target from $26 to $19.

Benzinga · 11/12/2019 11:21

Baird downgrades Cellular Biomedicine Gr (NASDAQ:CBMG) from Outperform to Neutral and lowers the price target from $26 to $19.